Search Results - Appleman, L.J

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate cancer (mCRPC)

    KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate canc... by Todenhöfer, T., Piulats, J.M., Ferrario, C., Linch, M.D., Stoeckle, M., Laguerre, B., Arranz, J.A., Fong, P.C.C., Berry, W.R., Emmenegger, U., Mourey, L., Mar, N., Appleman, L.J., Joshua, A.M., Conter, H.J., Li, X.T., Schloss, C., Poehlein, C.H., De Bono, J.S., Yu, E.Y.

    Published in European urology
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    7109 Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure

    7109 Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure by Tannir, N, Wong, Y, Kollmannsberger, C, Ernstoff, M.S, Perry, D.J, Appleman, L.J, Posadas, E, Qian, J, Ricker, J.L, Michaelson, D.M

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)

    122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-sm... by Marron, T.U., Naing, A., Mantia, C., Pennell, N., Kim, H.R., Villaruz, L., El-Khoueiry, A.B., Gerber, D.E., Qin, A., Kim, T-Y., Altan, M., Gandhi, L., Appleman, L.J., Yoon, S., Hill, J., Reichert, V., Masia, R., Harshman, L., Patnaik, A., Morgensztern, D.

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    870 A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (MCRPC)

    870 A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (MCRPC) by Petrylak, D, Smith, D.C, Appleman, L.J, Fleming, M, Hussain, A, Dreicer, R, Sartor, O, Shore, N, Vogelzang, N, Youssoufian, H, Stambler, N, Huang, K, Israel, R.J

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: